(Q35854081)

10 August 2017

1 reference

title

Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract (English)

1 reference

10 August 2017

Serenoa repens

1 reference

Habib FK

1

1 reference

10 August 2017

Wyllie MG

series ordinal

2

1 reference

10 August 2017

publication date

1 January 2004

1 reference

Prostate Cancer and Prostatic Diseases

10 August 2017

published in

1 reference

10 August 2017

volume

7

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

195-200

1 reference

Cytotoxicity and Anti-Hepatitis B Virus Activities of Saikosaponins fromBupleurumSpecies

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

International Consultation on Urological Diseases: a decade of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

Variations in Product Choices of Frequently Purchased Herbs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

Phytotherapy for benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

7 January 2021

Treatment of lower urinary tract symptoms suggestive of benign prostatic obstruction in real life practice in France

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

7 January 2021

Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

7 January 2021

Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

7 January 2021

Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract ofSerenoa repens (LSESr, Permixon�) in benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

7 January 2021

In vivo effect of the lipido-sterolic extract of Serenoa repens (Permixon) on mast cell accumulation and glandular epithelium trophism in the rat prostate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

7 January 2021

Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

7 January 2021

Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

7 January 2021

Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500746

7 January 2021

Identifiers

DOI

10.1038/SJ.PCAN.4500746

1 reference

10 August 2017

1 reference